CMA vs EDIT
CMA (CMA) versus Editas Medicine Inc (EDIT) — a side-by-side from cached financials, not a winner call.
CMA (CMA) common stock.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
CMA does not have a complete income-statement cache yet.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
EDIT currently screens at market cap $375.2M.
Not investment advice. Open the CMA and EDIT stock pages for the full models.
Not investment advice.